The Use of Sublingual Melatonin Premedication in Geriatric Cataract Surgery
Key facts
- Who runs it
- Al-Azhar University
- Where
- Egypt and Iraq2 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 60 people, planned
- Started
- 1 Sept 2025
- Planned end
- 15 Jun 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Sublingual Melatonin
- Sublingual Placebo
- Record updated
- 7 January 2026
Who can take part
- Age
- 60 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (2)Hide the full registry criteria
Who can take part
- • Age ≥ 60 years; American Society of Anesthesiologists (ASA) physical status I-III; Scheduled for unilateral cataract surgery under local anesthesia; Ability to understand and complete study-related questionnaires
Who cannot take part
- • Known allergy or hypersensitivity to melatonin; Chronic use of sedatives, hypnotics, or anxiolytics; History of sleep disorders or psychiatric illness; Visual or hearing impairment that would hinder communication; Emergency surgery or anticipated intraoperative complications
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Cataract surgery anesthesia
This trial is currently available in Iraq.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Cataract surgery is routinely performed with anesthesia care, whereas anesthesia care for other elective, low-risk, outpatient procedures is applied more selectively. We hypothesize that sublingual melatonin will provide superior anxiolysis and sedation while maintaining a high safety profile and minimizing hemodynamic disturbances.
The 2 groups in the trial
- Melatonin GroupExisting treatment, for comparison
a 6 mg sublingual tablet of melatonin will be administered for all patients at 60 minutes before surgery.
Treatment: Sublingual Melatonin
- Placebo GroupPlacebo, for comparison
the participants will be received a visually identical tablet containing inert ingredients at 60 minutes before surgery.
Treatment: Sublingual Placebo
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07036367, who can take part
- Record updated
- 7 January 2026